NCTN: A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor either as Initial Therapy or after Tamoxifen (NCIC-MA.17R)
Study ID: NCIC-MA.17R
NCT Number: NCT00754845
Canadian Cancer Trials Group (CCTG)
Submitted in collaboration with the NCTN/NCORP Data Archive
Trial Title: NCTN: A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor either as Initial Therapy or after Tamoxifen (NCIC-MA.17R)
Trial Description: RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating in women with breast cancer who have already received 5 years of aromatase inhibitor therapy.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating women with primary breast cancer who have received 5 years of aromatase inhibitor therapy.
Clinical data presented in the following publication(s):
- PMID 27264120
Disease type(s): Breast Neoplasm - Breast Cancer - Invasive
Clinical Dataset(s) included:
- NCT00754845-D1 (PMID 27264120): There is one dataset for NCIC-MA.17R's primary publication 27264120. This dataset contains number of major protocol violations, time from diagnosis to randomization, baseline characteristics, hormone receptor status, sites of recurrence, survival, toxicity, stratification factors, cause of death, and QOL data.
You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).
- Type: Double-Blind
- Archive: The database of Genotypes and Phenotypes (dbGaP)